NO312995B1 - Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom - Google Patents

Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom Download PDF

Info

Publication number
NO312995B1
NO312995B1 NO19971050A NO971050A NO312995B1 NO 312995 B1 NO312995 B1 NO 312995B1 NO 19971050 A NO19971050 A NO 19971050A NO 971050 A NO971050 A NO 971050A NO 312995 B1 NO312995 B1 NO 312995B1
Authority
NO
Norway
Prior art keywords
methyl
fluorophenyl
compound
pyrimidine
alkyl
Prior art date
Application number
NO19971050A
Other languages
English (en)
Norwegian (no)
Other versions
NO971050L (no
NO971050D0 (no
Inventor
Shoichi Chokai
Yojiro Ukai
Tomiyoshi Aoki
Kyoichi Ideguchi
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16685068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO312995(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of NO971050D0 publication Critical patent/NO971050D0/no
Publication of NO971050L publication Critical patent/NO971050L/no
Publication of NO312995B1 publication Critical patent/NO312995B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
NO19971050A 1994-09-09 1997-03-07 Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom NO312995B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21621494 1994-09-09
PCT/JP1995/001792 WO1996007641A1 (en) 1994-09-09 1995-09-08 Heterocyclic derivative and medicine

Publications (3)

Publication Number Publication Date
NO971050D0 NO971050D0 (no) 1997-03-07
NO971050L NO971050L (no) 1997-05-09
NO312995B1 true NO312995B1 (no) 2002-07-29

Family

ID=16685068

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19971050A NO312995B1 (no) 1994-09-09 1997-03-07 Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom

Country Status (19)

Country Link
US (2) US5945426A (de)
EP (1) EP0781766B1 (de)
JP (2) JP3036079B2 (de)
KR (1) KR100358245B1 (de)
CN (1) CN1118454C (de)
AT (1) ATE263154T1 (de)
BR (1) BR9508900A (de)
CA (1) CA2199518A1 (de)
DE (1) DE69532811T2 (de)
DK (1) DK0781766T3 (de)
ES (1) ES2218552T3 (de)
FI (1) FI970967L (de)
HU (1) HU221855B1 (de)
MX (1) MX9701765A (de)
NO (1) NO312995B1 (de)
NZ (1) NZ292269A (de)
PT (1) PT781766E (de)
RU (1) RU2128996C1 (de)
WO (1) WO1996007641A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1300056B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
WO2000010571A1 (en) * 1998-08-25 2000-03-02 Nippon Shinyaku Co., Ltd. Calcium channel antagonists
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
ATE289594T1 (de) * 2000-09-08 2005-03-15 Nippon Shinyaku Co Ltd Verfahren zur produktion von pyrimidinderivaten und geeignete zwischenprodukte
CN100415725C (zh) * 2000-09-19 2008-09-03 住友化学工业株式会社 嘧啶类化合物及其用途
GB0112810D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112802D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0119477D0 (en) 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
ATE325115T1 (de) 2002-08-19 2006-06-15 Glaxo Group Ltd Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
WO2004087712A1 (en) * 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research NEW PYRIMIDINE LINKED PYRROLO[2,1-c][1,4]BENZODIAZEPINES AS POTENTIAL ANTITUMOUR AGENTS
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RS20060018A (sr) 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
US6966680B2 (en) * 2003-11-28 2005-11-22 Edward Kratz Decorative lighting display with changeable shades and bulbs
PL1756084T3 (pl) * 2004-06-04 2009-06-30 Arena Pharm Inc Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
US20100160359A1 (en) * 2005-09-16 2010-06-24 Arena Pharmaceuticals, Inc. Modulators of Metabolism and the Treatment of Disorders Related Thereto
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP1941879A1 (de) * 2007-01-05 2008-07-09 PAION Deutschland GmbH Nervenschutzmittel zur Behandlung von neuronalen Schäden.
EP2008653A1 (de) 2007-06-28 2008-12-31 Charité-Universitätsmedizin Berlin Serotonerge Verbindungen zur Behandlung neuronaler Krankheiten
DE102007051090A1 (de) 2007-06-28 2009-01-08 Charité - Universitätsmedizin Berlin SSRI zur Behandlung neuronaler Krankheiten
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
EP3323818A1 (de) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
US11414594B2 (en) * 2019-04-09 2022-08-16 Gentex Corporation Low dimerizing viologen electrochromic compounds and devices

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3167553A (en) * 1963-05-08 1965-01-26 Searle & Co 2-amino-4-ethereal-5-methyl-6-phenylpyrimidines
BE756127A (fr) * 1969-09-12 1971-03-15 Hoechst Ag Ethers heterocycliques et leur preparation
JPS4921148B1 (de) * 1970-12-28 1974-05-30
US3937712A (en) * 1971-09-22 1976-02-10 Boehringer Ingelheim Gmbh (5-nitro-2-furyl)-pyridines
BE789099A (fr) * 1971-09-22 1973-03-21 Boehringer Sohn Ingelheim Nouveaux derives de la pyridine et procede pour les fabriquer
US4115575A (en) * 1973-02-20 1978-09-19 Ciba-Geigy Corporation 2-(3-Amino-2-hydroxy-propoxy)-pyrazines
SU1095878A3 (ru) * 1980-10-22 1984-05-30 Жансен Фармасетика Н.В. (Фирма) Способ получени производных 1-(4-арилциклогексил)пиперидина или их фармацевтически пригодных солей или их стереоизомерных форм
US4698340A (en) * 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
US4727073A (en) * 1984-10-01 1988-02-23 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives and composition of the same
AU3752589A (en) 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
KR930702312A (ko) * 1990-08-31 1993-09-08 아만 히데아키 피리미딘 유도체 및 의약
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
IL117659A (en) * 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same

Also Published As

Publication number Publication date
KR970705545A (ko) 1997-10-09
ATE263154T1 (de) 2004-04-15
NZ292269A (en) 1998-09-24
EP0781766A4 (de) 1998-01-14
JP3036079B2 (ja) 2000-04-24
DE69532811D1 (de) 2004-05-06
BR9508900A (pt) 1997-12-30
DE69532811T2 (de) 2005-03-17
CN1118454C (zh) 2003-08-20
KR100358245B1 (ko) 2003-11-28
RU2128996C1 (ru) 1999-04-20
ES2218552T3 (es) 2004-11-16
CA2199518A1 (en) 1996-03-14
EP0781766B1 (de) 2004-03-31
MX9701765A (es) 1997-06-28
WO1996007641A1 (en) 1996-03-14
FI970967A7 (fi) 1997-03-07
DK0781766T3 (da) 2004-07-26
US5945426A (en) 1999-08-31
JP2000136184A (ja) 2000-05-16
FI970967A0 (fi) 1997-03-07
NO971050L (no) 1997-05-09
EP0781766A1 (de) 1997-07-02
AU701395B2 (en) 1999-01-28
FI970967L (fi) 1997-03-07
AU3399695A (en) 1996-03-27
US6191149B1 (en) 2001-02-20
HU221855B1 (hu) 2003-02-28
CN1157609A (zh) 1997-08-20
JP3312616B2 (ja) 2002-08-12
HUT77779A (hu) 1998-08-28
NO971050D0 (no) 1997-03-07
PT781766E (pt) 2004-07-30

Similar Documents

Publication Publication Date Title
NO312995B1 (no) Pyrimidin- eller pyridinderivater samt anvendelse av slike derivater for fremstilling av legemidler for behandling avcerebrovaskul¶r sykdom
DE69718177T2 (de) Substituierte pyrimidinderivate und ihre pharmazeutische anwendung
JPWO1996007641A1 (ja) 複素環誘導体及び医薬
US7098211B2 (en) Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
CZ295346B6 (cs) Pyrimidinové sloučeniny, způsob jejich přípravy, farmaceutická kompozice a jejich použití pro léčbu poruch souvisejících s ligandy dopaminu D3
CA2000437A1 (en) 2-azetidinone derivatives
EP3348547B1 (de) Benzimidazol-derivate als nav 1.7 (natriumkanal, spannungsgesteuerten, typ ix, alpha untereinheit (scn9a)) inhibitoren zur behandlung von schmerz, dysurie und multiple sclerose
WO1995031442A1 (fr) Nouveau derive de pyrimidine
US6469168B1 (en) Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the active substance
JP4623354B2 (ja) 新規ピリミジン誘導体及び新規ピリジン誘導体
JPH09241161A (ja) 医 薬
US6610717B2 (en) Dihydropyridine derivatives
FI88300B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara diazinylpiperidinderivat av cykliska amider och imider
US6855716B2 (en) Dihydropyrimidine compounds and compositions containing the same
KR0130646B1 (ko) 이미다졸 부정맥증 치료제
CS276389B6 (en) Process for preparing derivatives of pyrimidinetrione
US5441948A (en) 1,3,4-benzotraizepin-5(4H)-one derivatives and process for the preparation thereof
JP2815218B2 (ja) ピリミジンジオン誘導体、およびそれを含有する抗不整脈剤
US5308848A (en) Pyrimidinedione derivatives and antiarrythmic agents containing the same
JPWO2000078730A1 (ja) 新規ジヒドロピリミジン誘導体
JPH06279373A (ja) アミノカルボン酸誘導体、その製造方法および用途
JPWO2000078720A1 (ja) 新規ジヒドロピリジン誘導体